Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2011, Article ID 391564, 6 pages
http://dx.doi.org/10.1155/2011/391564
Research Article

HER-2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain

1Oncology Department, Clinical University Hospital, 47005 Valladolid, Spain
2Pathology Department, Clinical University Hospital, 47005 Valladolid, Spain

Received 13 February 2011; Revised 21 August 2011; Accepted 5 September 2011

Academic Editor: Dirk Rades

Copyright © 2011 E. U. Cidon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Layke and P. P. Lopez, “Gastric cancer: diagnosis and treatment options,” American Family Physician, vol. 69, no. 5, pp. 1133–1145, 2004. View at Google Scholar · View at Scopus
  2. V. Archie, J. Kauh, D. V. Jones, V. Cruz, M. S. Karpeh, and C. R. Thomas, “Gastric cancer: standards for the 21st century,” Critical Reviews in Oncology/Hematology, vol. 57, no. 2, pp. 123–131, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. E. Van Cutsem, C. Van de Velde, A. Roth et al., “Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)—gastrointestinal cancer group,” European Journal of Cancer, vol. 44, no. 2, pp. 182–194, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. A. Shibata and J. Parsonnet, “Stomach cancer,” in Cancer Epidemiology and Prevention, D. Schottenfeld and J. F. Fraumeni Jr., Eds., pp. 707–720, Oxford University Press, Oxford, UK, 3rd edition, 2006. View at Google Scholar
  5. C. Hamashima, D. Shibuya, H. Yamazaki et al., “The Japanese guidelines for gastric cancer screening,” Japanese Journal of Clinical Oncology, vol. 38, no. 4, pp. 259–267, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. “Cáncer en cifras: cáncer gástrico,” Asociación Española Contra el Cáncer (AECC), 2002.
  7. A. Cervantes, V. Georgoulias, and A. Falcone, “State of the art treatment for gastric cancer: future directions,” European Journal of Cancer, Supplement, vol. 2, no. 7, pp. 40–47, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Grávalos and A. Jimeno, “HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target,” Annals of Oncology, vol. 19, no. 9, pp. 1523–1529, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. M. Scartozzi, E. Galizia, F. Freddari, R. Berardi, R. Cellerino, and S. Cascinu, “Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches,” Cancer Treatment Reviews, vol. 30, no. 5, pp. 451–459, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. P. M. Guy, J. V. Platko, L. C. Cantley, R. A. Cerione, and K. L. Carraway, “Insect cell-expressed p180(erbB3) possesses an impaired tyrosine kinase activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 17, pp. 8132–8136, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Tapia, K. Glatz, H. Novotny et al., “Close association between HER-2 amplification and overexpression in human tumors of non-breast origin,” Modern Pathology, vol. 20, no. 2, pp. 192–198, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. T. Takehana, K. Kunitomo, K. Kono et al., “Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay,” International Journal of Cancer, vol. 98, no. 6, pp. 833–837, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. M. Tateishi, T. Toda, Y. Minamisono, and S. Nagasaki, “Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma,” Journal of Surgical Oncology, vol. 49, no. 4, pp. 209–212, 1992. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Sasano, F. Date, A. Imatani, S. Asaki, and H. Nagura, “Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells,” Human Pathology, vol. 24, no. 6, pp. 584–589, 1993. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Yonemura, I. Ninomiya, A. Yamaguchi et al., “Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer,” Cancer Research, vol. 51, no. 3, pp. 1034–1038, 1991. View at Google Scholar · View at Scopus
  16. T. Ishida, M. Tsujisaki, Y. Hanzawa et al., “Significance of erbB-2 gene product as a target molecule for cancer therapy,” Scandinavian Journal of Immunology, vol. 39, no. 5, pp. 459–466, 1994. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Tokunaga, M. Onda, T. Okuda et al., “Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer,” Cancer, vol. 75, no. 6, pp. 1418–1425, 1995. View at Google Scholar · View at Scopus
  18. T. Funato, K. Kozawa, S. Fujimaki, T. Miura, and M. Kaku, “Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the HER-2/neu (c-erbB-2) gene,” Chemotherapy, vol. 47, no. 4, pp. 297–303, 2001. View at Publisher · View at Google Scholar
  19. I. García, F. Vizoso, A. Martín et al., “Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer,” Annals of Surgical Oncology, vol. 10, no. 3, pp. 234–241, 2003. View at Publisher · View at Google Scholar
  20. S. Uchino, H. Tsuda, K. Maruyama et al., “Overexpression of c-erbB-2 protein in gastric cancer: its correlation with long-term survival of patients,” Cancer, vol. 72, no. 11, pp. 3179–3184, 1993. View at Publisher · View at Google Scholar
  21. M. Tanner, M. Hollmén, T. T. Junttila et al., “Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab,” Annals of Oncology, vol. 16, no. 2, pp. 273–278, 2005. View at Publisher · View at Google Scholar · View at PubMed
  22. Y. J. Bang, E. Van Cutsem, A. Feyereislova et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Publisher · View at Google Scholar
  23. T. Yano, A. Ochiai, T. Doi et al., “Expression of HER-2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit,” Journal of Clinical Oncology, vol. 22, p. 14S, 2004. View at Google Scholar
  24. T. Kameda, W. Yasui, K. Yoshida et al., “Expression of ERBB2 in human gastric carcinomas: relationship between P185(ERBB2) expression and the gene amplification,” Cancer Research, vol. 50, no. 24, pp. 8002–8009, 1990. View at Google Scholar
  25. D. P. Hollywood and H. C. Hurst, “A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines,” EMBO Journal, vol. 12, no. 6, pp. 2369–2375, 1993. View at Google Scholar